Recommendations for the use of slow-release oral morphine as opioid agonist therapy

Evidence, Guidelines and Recommendations

Bringing together published evidence and both clinical and experiential expertise, these recommendations are intended to guide prescribers in the use of slow-release oral morphine (SROM, brand name Kadian) as opioid agonist therapy (OAT).

Details

Category
Evidence, Guidelines and Recommendations
Format
PDF Document
File Size
File not found.
Downloads
22
Added
Aug 25, 2025
Tags
Psychiatry
Pain
Mental Health
Substance Use Disorders
Primary Care
Internal Medicine
Emergency Medicine

Related Resources

Buprenorphine/Naloxone for Opioid Dependence: Clinical Practice Guideline
The objective of this guideline is to provide clinical recommendations for the initiation, maintenance and discontinuation of buprenorphine/naloxone maintenance treatment in the ambulatory treatment of adults and adolescents with opioid dependence in Ontario.